Interactions between striatal dopamine and adenosine receptors: effects of aminophylline on a pharmacological model of parkinson's disease
International Journal of Development Research
Interactions between striatal dopamine and adenosine receptors: effects of aminophylline on a pharmacological model of parkinson's disease
Received 03rd August, 2019; Received in revised form 26th September, 2019; Accepted 20th October, 2019; Published online 30th November, 2019
Copyright © 2019, Érica de Moraes Santos Corrêa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Parkinson's disease is primarily an extrapyramidal motor function disorder caused by severe degeneration of dopaminergic neurons in the substantia nigra. Current treatment for Parkinson's disease is based on dopaminergic therapy to reverse the effects of striatal dopamine depletion induced by nigro-striatal pathway destruction. The study of new therapies for Parkinson's disease focuses on non-dopaminergic systems inside the basal nuclei that go beyond injured nigrostriatal pathways. Several agents with therapeutic potential have been described, including agents acting on glutamatergic receptors, cannabinoids, opioids, α2-adrenergic receptors and nicotinic and muscarinic cholinergic receptors.The experimental evidencesuggests that the central stimulating properties performed by methylxanthines are neuroprotective and demonstrate beneficial therapeutic effects in the treatment of PD. These results corroborate the hypothesis of a strong interaction between adenosine and dopamine receptors in the striatal middle spinous neurons, playing opposite roles.
